Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.46 |
| ▸ | REN | P00797 | 7/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | NPFFR2 | Q9Y5X5 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601430 | 0.90 | MAPK8 (0.46) | MAPK8MAPK9MAPK10SLC6A2CALCRL | |
| SCHEMBL29506880 | 0.89 | CALCRL (0.52) | MAPK8MAPK9MAPK10CALCRLREN | |
| SCHEMBL29674936 | 0.87 | SLC6A2 (0.52) | MAPK8MAPK9MAPK10SLC6A2CALCRL | |
| SCHEMBL29726955 | 0.87 | SLC6A2 (0.55) | SLC6A2CALCRLOPRM1OPRD1OPRK1 | |
| SCHEMBL29634967 | 0.85 | MAPK8 (0.49) | MAPK8MAPK9MAPK10SLC6A2CALCRL | |
| SCHEMBL31071032 | 0.85 | CALCRL (0.55) | MAPK8MAPK9MAPK10CALCRLREN | |
| SCHEMBL31122251 | 0.84 | CALCRL (0.52) | MAPK8MAPK9MAPK10CALCRLREN | |
| SCHEMBL31122250 | 0.84 | CALCRL (0.53) | MAPK8MAPK9MAPK10CALCRLREN | |
| SCHEMBL31490515 | 0.84 | MAPK8 (0.54) | MAPK8MAPK9MAPK10SLC6A2CALCRL | |
| SCHEMBL29506907 | 0.84 | SLC6A2 (0.53) | MAPK8MAPK9MAPK10SLC6A2CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082283-A1 | LIGAND COMPOUND OF CYCLOPEPTIDE STRUCTURE, NUCLIDE MARKER THEREOF, PHARMACEUTICAL COMPOSITION, AND USE | 四川科伦博泰生物医药股份有限公司 | 2025-04-24 | — | — | WO | disclosed |
| EP-4274835-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2023-11-15 | — | — | EP | disclosed |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-10-06 | — | — | US | disclosed |
| WO-2022148843-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B PHARMACEUTICALS GMBH (DE) | 2022-07-14 | — | — | WO | disclosed |
| EP-3997104-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | 3B Pharmaceuticals GmbH (DE) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315554-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | MAPK8 763/4885MAPK9 669/4885MAPK10 1062/4885 |
| US-20230212549-A1 | COMPOUNDS COMPRISING A FIBROBLAST ACTIVATION PROTEIN LIGAND AND USE THEREOF | FIBP, FN1, TPX2 | MAPK8 763/4885MAPK9 669/4885MAPK10 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.